Quarterly ResultMay 7, 2026, 07:08 AM
Evolent Health Q1 Revenue $496.2M; Net Loss Narrows to $(26.6)M
AI Summary
Evolent Health announced its first quarter 2026 financial results, reporting revenue of $496.2 million, an increase from $483.6 million in the prior year period. The company significantly narrowed its net loss attributable to common shareholders to $(26.6) million from $(72.2) million year-over-year, though Adjusted EBITDA decreased to $22.1 million from $36.9 million. Evolent also announced two new revenue agreements, including an advanced imaging solution for 4.5 million lives and an expansion of its Oncology and Cardiology solution expected to generate over $200 million in annual revenue. The company reiterated its full-year 2026 revenue and Adjusted EBITDA guidance.
Key Highlights
- Q1 2026 Revenue was $496.2 million, up from $483.6 million in Q1 2025.
- Q1 2026 Net Loss attributable to common shareholders narrowed to $(26.6) million from $(72.2) million YoY.
- Q1 2026 Adjusted EBITDA was $22.1 million, down from $36.9 million in Q1 2025.
- New advanced imaging solution contract covers approximately 4.5 million lives, expected to go live in Q3.
- Oncology and Cardiology solution expansion expected to generate over $200 million of annual revenue, live in Q3.
- Full Year 2026 Revenue Guidance reiterated at $2.4 billion to $2.6 billion.
- Full Year 2026 Adjusted EBITDA Guidance reiterated at $110 million to $140 million.
- Q1 2026 Basic and diluted loss per share was $(0.24), improved from $(0.63) in Q1 2025.